HK1209331A1 - Cells for producing recombinant iduronate-2-sulfatase -2- - Google Patents

Cells for producing recombinant iduronate-2-sulfatase -2-

Info

Publication number
HK1209331A1
HK1209331A1 HK15110031.3A HK15110031A HK1209331A1 HK 1209331 A1 HK1209331 A1 HK 1209331A1 HK 15110031 A HK15110031 A HK 15110031A HK 1209331 A1 HK1209331 A1 HK 1209331A1
Authority
HK
Hong Kong
Prior art keywords
sulfatase
cells
producing recombinant
recombinant iduronate
iduronate
Prior art date
Application number
HK15110031.3A
Other languages
English (en)
Chinese (zh)
Inventor
‧博爾戈
‧哈特萊因
Original Assignee
Shire Human Genetic Therapies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Human Genetic Therapies filed Critical Shire Human Genetic Therapies
Publication of HK1209331A1 publication Critical patent/HK1209331A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004Oxidoreductases (1.)
    • C12N9/0051Oxidoreductases (1.) acting on a sulfur group of donors (1.8)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • C12P21/06Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y108/00Oxidoreductases acting on sulfur groups as donors (1.8)
    • C12Y108/99Oxidoreductases acting on sulfur groups as donors (1.8) with other acceptors (1.8.99)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y301/00Hydrolases acting on ester bonds (3.1)
    • C12Y301/06Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06013Iduronate-2-sulfatase (3.1.6.13)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/10Plasmid DNA
    • C12N2800/106Plasmid DNA for vertebrates
    • C12N2800/107Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
HK15110031.3A 2012-06-29 2015-10-14 Cells for producing recombinant iduronate-2-sulfatase -2- HK1209331A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261666719P 2012-06-29 2012-06-29
PCT/US2013/048571 WO2014005019A2 (en) 2012-06-29 2013-06-28 Cells for producing recombinant iduronate-2-sulfatase

Publications (1)

Publication Number Publication Date
HK1209331A1 true HK1209331A1 (en) 2016-04-01

Family

ID=49778522

Family Applications (2)

Application Number Title Priority Date Filing Date
HK15110031.3A HK1209331A1 (en) 2012-06-29 2015-10-14 Cells for producing recombinant iduronate-2-sulfatase -2-
HK15110644.2A HK1209651A1 (en) 2012-06-29 2015-10-28 Cells for producing recombinant iduronate-2-sulfatase -2-

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK15110644.2A HK1209651A1 (en) 2012-06-29 2015-10-28 Cells for producing recombinant iduronate-2-sulfatase -2-

Country Status (27)

Country Link
US (3) US9150841B2 (pt)
EP (1) EP2874649B1 (pt)
JP (3) JP6067849B2 (pt)
KR (1) KR101710487B1 (pt)
CN (2) CN107267460A (pt)
AU (3) AU2013282400B2 (pt)
BR (1) BR112014032560B1 (pt)
CA (1) CA2877521C (pt)
CL (1) CL2014003568A1 (pt)
CO (1) CO7240394A2 (pt)
CR (1) CR20140586A (pt)
DO (1) DOP2014000298A (pt)
EA (2) EA202090805A1 (pt)
ES (1) ES2718346T3 (pt)
GT (1) GT201400302A (pt)
HK (2) HK1209331A1 (pt)
IL (3) IL236343A (pt)
MX (2) MX366155B (pt)
MY (2) MY157086A (pt)
NZ (2) NZ734670A (pt)
PE (1) PE20150957A1 (pt)
PH (2) PH12014502868A1 (pt)
SG (2) SG10201509397SA (pt)
TR (1) TR201904435T4 (pt)
UA (1) UA118955C2 (pt)
WO (1) WO2014005019A2 (pt)
ZA (1) ZA201409396B (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
HUE058896T2 (hu) 2010-10-01 2022-09-28 Modernatx Inc N1-metil-pszeudo-uracilt tartalmazó ribonukleinsavak és azok felhasználásai
US8710200B2 (en) 2011-03-31 2014-04-29 Moderna Therapeutics, Inc. Engineered nucleic acids encoding a modified erythropoietin and their expression
US20160145589A1 (en) 2011-06-24 2016-05-26 Green Cross Corporation Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof
CN104114572A (zh) 2011-12-16 2014-10-22 现代治疗公司 经修饰的核苷、核苷酸和核酸组合物
US9303079B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
DE18200782T1 (de) 2012-04-02 2021-10-21 Modernatx, Inc. Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
WO2013166339A1 (en) * 2012-05-02 2013-11-07 Life Technologies Corporation High yield transient expression in mammalian cells using unique pairing of high density growth and transfection medium and expression enhancers
US9150841B2 (en) * 2012-06-29 2015-10-06 Shire Human Genetic Therapies, Inc. Cells for producing recombinant iduronate-2-sulfatase
KR101380740B1 (ko) 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 이듀로네이트-2-설파타제의 정제
US20140004097A1 (en) * 2012-06-29 2014-01-02 Shire Human Genetic Therapies, Inc. Method of producing recombinant iduronate-2-sulfatase
WO2014028429A2 (en) 2012-08-14 2014-02-20 Moderna Therapeutics, Inc. Enzymes and polymerases for the synthesis of rna
EP4074834A1 (en) 2012-11-26 2022-10-19 ModernaTX, Inc. Terminally modified rna
EP2968391A1 (en) 2013-03-13 2016-01-20 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
EP2971010B1 (en) 2013-03-14 2020-06-10 ModernaTX, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
US9550972B2 (en) 2014-09-29 2017-01-24 General Electric Company Devices, systems and methods for automated cell culturing
EP3101125A1 (en) * 2015-06-05 2016-12-07 Laboratorios Del Dr. Esteve, S.A. Adenoassociated virus vectors for the treatment of mucopolysaccharidoses
EP3359670B2 (en) 2015-10-05 2024-02-14 ModernaTX, Inc. Methods for therapeutic administration of messenger ribonucleic acid drugs
EP3692070A1 (en) 2017-10-02 2020-08-12 Denali Therapeutics Inc. Fusion proteins comprising enzyme replacement therapy enzymes
JP7060235B2 (ja) * 2018-05-18 2022-04-26 国立大学法人広島大学 変異型イズロン酸-2-スルファターゼの機能回復薬剤のスクリーニング方法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK6488D0 (da) 1988-01-07 1988-01-07 Novo Industri As Enzymer
US5310646A (en) 1988-05-13 1994-05-10 Regents Of The University Of Minnesota Method for the detection of mucopolysaccharide storage diseases
US5932211A (en) 1991-11-12 1999-08-03 Women's And Children's Hospital Glycosylation variants of iduronate 2-sulfatase
EP0750511B1 (en) 1994-03-16 2003-06-11 The Regents Of The University Of California Treating inflammation via the administration of specific sulfatase enzymes and/or sulfation inhibitor
US5863782A (en) 1995-04-19 1999-01-26 Women's And Children's Hospital Synthetic mammalian sulphamidase and genetic sequences encoding same
DE19527054A1 (de) 1995-07-26 1997-01-30 Behringwerke Ag Verfahren zur Charakterisierung der Glycosylierung von Glycoproteinen sowie zur in-vitro Bestimmung der Bioverfügbarkeit von Glycoproteinen
EP2243827B2 (en) 1996-08-30 2017-11-22 Life Technologies Corporation Serum-free mammalian cell culture medium, and uses thereof
US7368531B2 (en) 1997-03-07 2008-05-06 Human Genome Sciences, Inc. Human secreted proteins
US7083793B2 (en) 1999-02-26 2006-08-01 Millennium Pharmaceuticals, Inc. Tango 243 polypeptides and uses thereof
WO2000050443A2 (en) 1999-02-26 2000-08-31 Millennium Pharmaceutcals, Inc. Secreted proteins and uses thereof
ATE348173T1 (de) 1999-04-26 2007-01-15 Genentech Inc Zellenzuchtverfahren für glycoproteine
JP2002017376A (ja) 1999-07-08 2002-01-22 Herikkusu Kenkyusho:Kk 分泌蛋白質、または膜蛋白質
AU7099200A (en) 1999-09-03 2001-04-10 Human Genome Sciences, Inc. 52 human secreted proteins
US6780627B1 (en) 2000-01-31 2004-08-24 Millennium Pharmaceuticals, Inc. 22438, 23553, 25278, and 26212 novel human sulfatases
JP2004502404A (ja) 2000-02-17 2004-01-29 インサイト・ゲノミックス・インコーポレイテッド ヒトキナーゼ
AU2001252917A1 (en) 2000-03-17 2001-10-03 Human Genome Sciences, Inc. 7 human ovarian and ovarian cancer associated proteins
AU2001259063A1 (en) 2000-04-12 2001-10-30 Human Genome Sciences, Inc. Albumin fusion proteins
US20030148920A1 (en) 2000-12-27 2003-08-07 Steven Rosen Sulfatases and methods of use thereof
AU2002317700A1 (en) 2001-06-07 2002-12-16 Hemebiotech A/S Production of recombinant human arylsulfatase a
AU2003265235A1 (en) 2002-04-26 2003-12-19 Genetech, Inc. Non-affinity purification of proteins
US6890736B1 (en) 2002-09-20 2005-05-10 Immunex Corporation Methods for producing proteins in cultured cells
EP1575998A4 (en) 2002-12-23 2007-07-25 Bristol Myers Squibb Co PROCESS FOR CULTIVATING MAMMALIAN CELLS FOR PROTEIN PRODUCTION
WO2004072275A2 (en) 2003-02-11 2004-08-26 Transkaryotic Therapies, Inc. Diagnosis and treatment of multiple sulfatase deficiency and other using a formylglycine generating enzyme (fge)
US20050019914A1 (en) 2003-07-24 2005-01-27 Aventis Pharma Deutschland Gmbh Perfusion process for producing erythropoietin
WO2005113765A2 (en) 2004-05-06 2005-12-01 Biomarin Pharmaceutical Inc. Methods of activation of sulfatases and methods and compositions of using the same
CA2609060C (en) 2005-06-03 2014-07-15 Urs Weber Production of recombinant il-18 binding protein
CA2645739A1 (en) 2006-03-20 2007-09-27 Medarex, Inc. Protein purification
KR101744142B1 (ko) * 2008-01-18 2017-06-07 바이오마린 파머수티컬 인크. 활성이고 높은 정도로 인산화된 인간 리소좀 술파타아제 효소의 제조 및 그 용도
DK2485761T3 (da) 2009-10-09 2019-05-06 Armagen Inc Fremgangsmåder og sammensætninger til øgning af iduronat-2-sulfatase-aktivitet i CNS
KR20120093202A (ko) * 2009-10-09 2012-08-22 다우 글로벌 테크놀로지스 엘엘씨 단열식 플러그 흐름 반응기 및 염화 및/또는 불화 프로펜 및 고급 알켄의 제조 방법
WO2011108451A1 (ja) 2010-03-01 2011-09-09 日本ケミカルリサーチ株式会社 遺伝子ノックアウト細胞を用いた組換え体リソソーム酵素の製造方法
JP6045492B2 (ja) 2010-06-25 2016-12-14 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド イズロン酸−2−スルファターゼのcns送達のための方法および組成物
WO2012101671A1 (en) 2011-01-25 2012-08-02 Jcr Pharmaceuticals Co., Ltd. Method for production of human recombinant iduronate 2-sulfatase
KR101158673B1 (ko) 2011-06-24 2012-07-03 주식회사 지씨바이오 재조합 인간 이듀로네이트-2-설파타아제를 포함하는 조성물, 제제 및 이의 제조방법
KR101380740B1 (ko) 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 이듀로네이트-2-설파타제의 정제
US20140004097A1 (en) 2012-06-29 2014-01-02 Shire Human Genetic Therapies, Inc. Method of producing recombinant iduronate-2-sulfatase
US9150841B2 (en) * 2012-06-29 2015-10-06 Shire Human Genetic Therapies, Inc. Cells for producing recombinant iduronate-2-sulfatase

Also Published As

Publication number Publication date
PE20150957A1 (es) 2015-07-15
CN104540517A (zh) 2015-04-22
EP2874649B1 (en) 2019-01-02
EA202090805A1 (ru) 2020-11-30
EA201492183A1 (ru) 2015-06-30
AU2013282400A1 (en) 2015-01-29
IL236343A0 (en) 2015-02-26
EP2874649A4 (en) 2016-05-04
TR201904435T4 (tr) 2019-05-21
IL254560A0 (en) 2017-11-30
US9150841B2 (en) 2015-10-06
US20160053238A1 (en) 2016-02-25
IL254560B (en) 2020-05-31
AU2016200460A1 (en) 2016-02-18
AU2016200460B2 (en) 2017-11-02
SG10201509397SA (en) 2015-12-30
KR20150030242A (ko) 2015-03-19
UA118955C2 (uk) 2019-04-10
PH12016500011A1 (en) 2019-08-14
JP6067849B2 (ja) 2017-01-25
PH12014502868B1 (en) 2015-02-23
CA2877521A1 (en) 2014-01-03
IL274266B (en) 2021-04-29
US20180010108A1 (en) 2018-01-11
PH12014502868A1 (en) 2015-02-23
KR101710487B1 (ko) 2017-02-27
MX366155B (es) 2019-06-28
CO7240394A2 (es) 2015-04-17
JP2016105737A (ja) 2016-06-16
US20140004593A1 (en) 2014-01-02
JP2015521848A (ja) 2015-08-03
IL236343A (en) 2017-10-31
JP6755272B2 (ja) 2020-09-16
CR20140586A (es) 2015-04-06
IL274266A (en) 2020-06-30
MY189314A (en) 2022-02-04
AU2018200710A1 (en) 2018-02-22
CL2014003568A1 (es) 2015-04-24
BR112014032560B1 (pt) 2022-04-26
JP2018088933A (ja) 2018-06-14
ZA201409396B (en) 2018-05-30
MX2015000189A (es) 2015-04-08
MY157086A (en) 2016-04-19
SG11201408702VA (en) 2015-02-27
AU2018200710B2 (en) 2019-11-14
JP6302499B2 (ja) 2018-03-28
ES2718346T3 (es) 2019-07-01
WO2014005019A2 (en) 2014-01-03
US9719074B2 (en) 2017-08-01
NZ734670A (en) 2019-12-20
CA2877521C (en) 2021-06-01
AU2013282400B2 (en) 2016-02-04
BR112014032560A2 (pt) 2018-03-06
GT201400302A (es) 2019-05-22
WO2014005019A3 (en) 2014-02-27
EA035511B1 (ru) 2020-06-26
DOP2014000298A (es) 2015-03-31
NZ703137A (en) 2017-08-25
MX336716B (es) 2016-01-28
EP2874649A2 (en) 2015-05-27
CN107267460A (zh) 2017-10-20
HK1209651A1 (en) 2016-04-08

Similar Documents

Publication Publication Date Title
IL274266B (en) Cells for the production of recombinant iduronate-2-sulfatase
HK1211623A1 (en) Cell lines
EP2919313A4 (en) SOLID ELECTROLYTE
ZA201503358B (en) Structure
EP2876715A4 (en) FUEL CELL
EP2911230A4 (en) CELL
EP2698839A4 (en) BLOCK OF CELLS
HK1215645A1 (zh) 小區重選
EP2707886A4 (en) ELECTROLYTE
EP2831949A4 (en) SODIUM OXYGEN CELLS
EP2899786A4 (en) FUEL CELL
GB201319035D0 (en) Spolier structure
EP2830138A4 (en) BIO FUEL CELL
EP2919308A4 (en) Polyelectrolyte FUEL CELL
EP2835852A4 (en) FUEL CELL
EP2830130A4 (en) FUEL CELL
EP2863459A4 (en) FLAT CELL
GB201220058D0 (en) Cell differentiation
EP2805544A4 (en) CELL HANDOVER
HUP1300640A2 (en) Belt-mounting structure
EP2882020A4 (en) FUEL CELL
GB2500031B (en) Fuel cells
EP2863460A4 (en) FUEL CELL
EP2871919A4 (en) STRUCTURE
EP2808929A4 (en) FUEL CELL